- Offers practical guidance on FDG PET/CT interpretation in multiple myeloma
- Identifies and explains the most frequent pitfalls
- Aids recognition of false positive findings and accurate estimation of disease extension
- Describes emerging functional imaging techniques, including DWI MR and non-FDG tracers
This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients.
This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/or evaluating response to therapy.
In this challenging context,
Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.
Table of Contents- Multiple Myeloma: Clinical Aspects
- What Does a Clinician Need from New Imaging Procedures?
- FDG PET in Multiple Myeloma
- Role of Standard Magnetic Resonance Imaging
- Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A New Era for Whole Body Imaging in Myeloma?
- CXCR4 Imaging in Multiple Myeloma
- PET/CT with Standard Non-FDG Tracers in Multiple Myeloma
- The Issue of Interpretation
- Clinical Teaching Cases: FDG PET/CT
